Postmenopausal Osteoporosis: The Role of Immune System Cells

Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70124 Bari, Italy.
Clinical and Developmental Immunology (Impact Factor: 2.93). 05/2013; 2013(7):575936. DOI: 10.1155/2013/575936
Source: PubMed


In the last years, new evidences of the relationship between immune system and bone have been accumulated both in animal models and in humans affected by bone disease, such as rheumatoid arthritis, bone metastasis, periodontitis, and osteoporosis. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and susceptibility to fractures. The combined effects of estrogen deprivation and raising of FSH production occurring in menopause cause a marked stimulation of bone resorption and a rapid bone loss which is central for the onset of postmenopausal osteoporosis. This review focuses on the role of immune system in postmenopausal osteoporosis and on therapeutic strategies targeting osteoimmunology pathways.

Download full-text


Available from: Maria Felicia Faienza, Jun 09, 2014
  • Source
    • "Osteoporosis is a disease characterized by low bone density and poor bone quality, which causes reduced bone strength and an increased risk of fractures (Faienza et al. 2013). These fractures cause elderly people to become bedridden (Hagino et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipopolysaccharide from Pantoea agglomerans (LPSp) facilitates Ca and P turnover in chicken calvaria and femurs. This study investigated osteoporosis prevention by the oral administration of LPSp in mice and in double-blind clinical tests. Using ovariectomized (OVX) osteoporosis mice model, we investigated the effects of LPSp on the bone density and Ca concentration after ingesting LPSp-containing water for 4 weeks. Oral administration of LPSp tended to suppress the decline in the bone density and the cortical bone thickness in the OVX mice. Moreover, the Ca concentrations were maintained in the OVX-LPSp mice. The effects of LPSp on bone turnover were tested in randomized and double-blind clinical test subjects, who were healthy women aged 40–79 years. The subjects ingested either soy milk without LPSp (control group) or with LPSp (LPSp group) for 3 months. The results showed that the LPSp group on premenopause maintained their bone density compared with the control group pre- and postmenopause. Moreover, these effects were maintained for 2 months postobservation. LPSp maintains bone volume and density in vivo. Thus, a combination of soy milk and LPSp may be useful for osteoporosis prevention.
    Full-text · Article · Nov 2014 · Food Science & Nutrition
  • Source
    • "Postmenopausal osteoporosis (PMO) commonly occurs in women approximately 10 years after the onset of menopause. In human, depletion of estrogen has been shown as a key factor in pathogenesis of PMO [3], [4], [5], [6]. Supplement with estrogen in postmenopausal women can prevent or attenuate bone loss in postmenopausal women [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In human, a reduction in estrogen has been proposed as one of the key contributing factors for postmenopausal osteoporosis. Rodents are conventional models for studying postmenopausal osteoporosis, but the major limitation is that ovariectomy is needed to mimic the estrogen decline after menopause. Interestingly, in medaka fish (Oryzias latipes), we observed a natural drop in plasma estrogen profile in females during aging and abnormal spinal curvature was apparent in old fish, which are similar to postmenopausal women. It is hypothesized that estrogen associated disorders in bone metabolism might be predicted and prevented by estrogen supplement in aging O. latipes, which could be corresponding to postmenopausal osteoporosis in women.
    Full-text · Article · Feb 2014 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Corin is a cardiac protease that activates the natriuretic peptides. Corin is also expressed in chrondrocytes and marrow-derived mesenchymal stem cells that undergo osteogenic differentiation, suggesting a potential role of corin in bone formation and homeostasis. To test if corin levels are altered in patients with bone disease, we used ELISA to measure corin and osteocalcin levels in serum samples from healthy controls (n=134) and patients with osteopenia (n=53) and osteoporosis (n=101). In patients with osteopenia and osteoporosis, serum corin levels were 510 ± 228 and 478 ± 183pg/ml, respectively, which were significantly lower than that in healthy controls (682 ± 240pg/ml) (both p values <0.001). The reduced serum corin levels were found in both male and female patients. In multiple linear regression analysis, bone mineral density was identified as an independent predictor for serum corin levels. In patients with osteopenia and osteoporosis, but not normal controls, a negative correlation was found between serum corin and osteocalcin levels. Serum corin levels were reduced in patients with osteoporosis and the reduction was associated with high rates of bone turnover. Low serum corin levels may reflect impaired bone homeostasis in patients with osteoporosis.
    No preview · Article · Sep 2013 · Clinica chimica acta; international journal of clinical chemistry
Show more